Tango Therapeutics Hits New 52-Week High at $33.00, Soars 359.5%

Tango Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 33.00 on June 15, 2026. This achievement marks a remarkable 359.5% increase in the stock's performance over the past year, significantly outpacing the S&P 500's growth of 26.39% during the same period. With a market capitalization of USD 2,748 million, Tango Therapeutics has positioned itself as a notable entity within its industry. Despite being a loss-making company, it continues to attract attention due to its substantial price appreciation. The stock's price-to-book ratio stands at 7.94, indicating a premium valuation relative to its book value. While the company does not offer a dividend, its financial metrics, including a debt-to-equity ratio of -0.98 and a return on equity of -29.35%, reflect its current operational stance. The stock's previous 52-week low was recorded at USD 4.40, highlighting the significant upward trajectory it has experienced.